Our Blog

USFDA grants fee waiver to Cyclopharm (ASX:CYC) for Technegas application

14 Apr 2020 – Cyclopharm (ASX:CYC) is pleased to announce that the United States Food and Drug Administration (USFDA) has granted the Company a full application fee waiver of USD $2.9 million related to its recently submitted New Drug Application (NDA) for Technegas.

Source: Finance News Network

Share this post